(Q36251046)

English

Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

object named as

Shenying Fang

3

0 references

Mariana Chavez-MacGregor

object named as

Mariana Chavez-MacGregor

1

0 references

Sharon H. Giordano

object named as

Sharon H Giordano

6

0 references

Gabriel N Hortobagyi

5

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Hui Zhao

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Tomasz P Srokowski

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

24 February 2011

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

117

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

3641-3649

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Venous thromboembolic events and erythropoiesis-stimulating agents: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Development and validation of a predictive model for chemotherapy-associated thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

The cardiovascular effects of erythropoietin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Development of a comorbidity index using physician claims data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Erythropoietin and systemic hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

1 October 2017

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25972

21 January 2018

Venous thromboembolism in patients with active cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

22 September 2018

Potential for cancer related health services research using a linked Medicare-tumor registry database.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3448281

22 September 2018

Recombinant erythropoietin increases blood pressure in experimental hypertension and uraemia without change in vascular cytosolic calcium

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weighing the hazards of erythropoiesis stimulation in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin, the FDA, and oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stopping metastases at their source

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25972

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

release_wtpm5pxf6bbmpp4f24luno24ku

1 reference

https://api.fatcat.wiki/v0/release/wtpm5pxf6bbmpp4f24luno24ku

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36251046&oldid=2001129627"